Our take
SS Innovations is growing quickly. Its SSi Mantra had 224 systems installed across twelve countries and 12,272 surgeries performed by June 30, 2026, including cardiac, pediatric, and long-distance telesurgery cases.1 For hospitals in markets where the leading systems are too expensive, it is a credible alternative.
For US buyers it is not yet an option. The company answered an FDA request for more information in October 2026 and expects the agency to finish reviewing its 510(k) submission in the first quarter of 2027, for an initial gallbladder removal indication.2
Scores by criterion
Each criterion is defined on our methodology page.
Who uses SS Innovations and what it's for
SS Innovations has an established presence in India and is expanding abroad.4 The first SSi Mantra went to the Rajiv Gandhi Cancer Institute and Research Centre in New Delhi in 2022.3 By mid-2026 its installed base covered twelve countries, and its cumulative surgeries included 175 telesurgeries, 637 cardiac procedures, and 222 pediatric surgeries.1
Buyers compare the SSi Mantra with Intuitive Surgical's da Vinci, the market leader, and with other new multi-arm systems. The company's case rests on price and on breadth, including cardiac surgery.3,4
One system for general and cardiac surgery
The SSi Mantra is a surgical robot that SS Innovations describes as cost-efficient and suited to a wide range of procedures, including cardiac surgery.4 It is a modular system with 3 to 5 robotic arms, an open surgeon console, and a 3D 4K monitor.2 Installations rose to 30 in the second quarter of 2026, up from 23 a year earlier, and quarterly surgeries rose to 2,528 from 1,042.1
Long-distance telesurgery
On July 29, 2026, surgeons led by founder Sudhir Srivastava used the SSi Mantra to perform a sleeve gastrectomy remotely from Bucaramanga, Colombia, on a patient in Indore, India, across more than 13,600 miles of fiber network. The company says that broke its own earlier distance record.1
Pricing far below the market leader
SS Innovations does not publish a list price. Business Standard reported in 2022 that the SSi Mantra cost around Rs 4.5 crore against Rs 15 crore for a da Vinci, less than a third of the price.3 That is a useful reference point, but it is four years old and in rupees, so we treat it as a partial price disclosure.
Competition
SS Innovations competes with the established makers of multi-arm surgical robots. Intuitive dominates the category, and Medtronic and CMR Surgical are the other large challengers.
| Company | Product | Pricing model | Deployment footprint | Where SS Innovations wins or loses |
|---|---|---|---|---|
| SS Innovations | SSi Mantra modular surgical robot | Less than a third of a da Vinci's price in a 2022 report3 | 224 systems in twelve countries by June 30, 2026; not yet FDA cleared1,2 | Lower price and telesurgery; no US clearance yet |
| Intuitive (da Vinci) | da Vinci multi-port and single-port surgical systems6 | Sales plus leases, many with usage-based payments6 | About 12,094 systems installed at September 30, 20266 | Intuitive wins on installed base, training, and US clearances. SSi wins on price in markets where da Vinci is out of reach. |
| Medtronic (Hugo) | Hugo robotic-assisted surgery system7 | Not published7 | FDA cleared in December 2025 for urologic procedures7 | Medtronic wins on a US clearance and a global sales force. SSi wins on cost and cardiac cases. |
| CMR Surgical (Versius) | Versius Plus modular surgical robot8 | Not published8 | 45,000 cases worldwide; FDA 510(k) for gallbladder removal8 | CMR wins on a US clearance for the same first indication SSi is seeking. SSi wins on price. |
Source: Robotics Reviewed analysis of company product pages, filings, and announcements, October 2026.
Limits
Not cleared for sale in the United States. FDA review of the 510(k) is expected in the first quarter of 2027.2
Losses continue. The company reported a net loss of $2.7 million in the second quarter of 2026, and second-quarter gross margin fell to 50.9% from 59.1% a year earlier, although first-half gross margin rose to 49.6% from 46.3%. It had $13.6 million in cash and no long-term debt on June 30, 2026.1
The only public price reference is a 2022 press report.3
What customers say
Where it helps
We found no independent surgeon or hospital reviews to quote. The case for the system in public material rests on volume: 12,272 surgeries across 224 installations, and growth in procedures per system.1
Where it falls short
The drawbacks in public material are the lack of US clearance, a lower gross margin in the second quarter of 2026, and continued net losses.2,1
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation. Based on: SS Innovations financial results and FDA update, and Business Standard reporting.
Leadership
Sudhir Srivastava
Founder, chairman, and chief executive officerDr. Srivastava is a cardiac surgeon who was working in Texas, returned to India in 2011, and started SS Innovations in 2014.3,5
Vishwa Srivastava
Chief executive officer, Asia PacificDr. Vishwa Srivastava sits on the boards of both the US parent and the Indian operating company and leads the Asia Pacific business.5
Sources
- SS Innovations, Second quarter 2026 financial results, August 13, 2026, accessed October 31, 2026
- SS Innovations, Response to FDA request for additional information on the SSi Mantra 510(k), October 13, 2026, accessed October 31, 2026
- Business Standard, The SSI Mantra: India’s own surgical robot boasts cheaper price tag, September 15, 2022, accessed October 31, 2026
- SS Innovations, Investor overview, accessed October 31, 2026
- SS Innovations, Leadership, accessed October 31, 2026
- Intuitive, Form 10-Q for the quarter ended September 30, 2026, SEC, accessed October 31, 2026
- Medtronic, FDA clearance of Hugo robotic-assisted surgery system for urologic surgical procedures, December 3, 2025, accessed October 31, 2026
- CMR Surgical, Homepage, accessed October 31, 2026
